JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
NASDAQ · Pharmaceuticals · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 3, 2026
$235,67
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$128,8052tyg. minimum
$266,3852tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$15.27B
P/E (TTM)
16.1
EPS (TTM)
$14.63
Przychody (TTM)
$4.60B
Twoje odznaki
Zakres 52 tyg.
$129–$266
Ocena Analityków
BUY
Cena Docelowa
$294
P/E
16.1
ROE
22.1%
Marża Zysku Netto
20.4%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
JAZZ Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$235.67
Kapitalizacja Rynkowa (MRQ)
$15.27B
P/E (TTM)
16.1
EPS (TTM)
$14.63
Przychody (TTM)
$4.60B
ROE (TTM)
22.1%
D/E Dług/Kapitał (MRQ)
0.9
Zakres 52 tyg.
$129–$266
JAZZ Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O Jazz Pharmaceuticals plc - Ordinary Shares Przegląd firmy z Wikipedii
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaPharmaceuticals
pracownicy2 890
krajIE
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$4.27B2016-12-31 → 2025-12-31
EPS$-5.842016-12-31 → 2025-12-31
Marża netto20.4%
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | JAZZ | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 16.1średnia z 5 lat ≈-12.5 | ≈-12.5 | · | · | |
| P/S (TTM) | 3.3 | · | · | · | |
| P/B (MRQ) | 3.2 | · | · | · | |
| Cena / FCF (TTM) | 9.6 | · | · | · | |
| Cena / Przepływy pieniężne (TTM) | 9.2 | · | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 19.8 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | JAZZ | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 19.5% | · | · | · | |
| Marża przed opodatkowaniem (TTM) | 15.8% | · | · | · | |
| Marża Zysku Netto (TTM) | 20.4% | · | · | · | |
| ROA (TTM) | 8.5% | · | · | · | |
| ROE (TTM) | 22.1% | · | · | · |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | JAZZ | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.9 | · | · | · | |
| Wskaźnik bieżący (MRQ) | 1.8 | · | · | · | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.7 | · | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | JAZZ | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 4.9%średnia z 5 lat ≈13.0% | ≈13.0% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 5.3%średnia z 5 lat ≈10.8% | ≈10.8% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 12.5% | · | · | · | |
| EPS YoY | 41.8% | · | · | · | |
| Net Income YoY (Zysk Netto R/R) | 35.0% | · | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | 13.1% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | 20.2% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | JAZZ | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue / Employee (Przychody / pracownika) | ≈$1.5M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-1.6%
Następny raport
Lis 03, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 3, 2026 | $5.71 | $6.30 | -9.4% |
| 31 marca 2026 | $6.34 | $4.66 | 36.1% | |
| 31 grudnia 2025 | $6.64 | $6.65 | -0.11% | |
| 30 września 2025 | $8.13 | $6.04 | 34.7% | |
| 30 czerwca 2025 | $-8.25 | $-7.76 | -6.4% | |
| 31 marca 2025 | $1.68 | $4.75 | -64.6% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | · | 60,696,000 | 61,200,000 | 61,000,000 | · | 61,414,000 | 62,882,000 | 62,537,000 | · | 63,114,000 | 63,991,000 | 63,494,000 | · | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | · | 61,606,000 | 61,200,000 | 61,000,000 | · | 63,174,000 | 69,625,000 | 62,537,000 | · | 71,293,000 | 73,540,000 | 73,771,000 | · | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $74.10 | $72.29 | · | $65.18 | $61.12 | $67.75 | · | $69.01 | $60.94 | $58.65 | · | $55.44 | · | · | · | · | |
| Revenue / Share | $17.41 | $16.17 | · | $18.28 | $17.09 | $14.72 | · | $16.70 | $14.70 | $14.42 | · | $13.64 | $13.02 | $12.10 | · | $14.98 | |
| Cash Flow / Share | · | $6.18 | · | · | · | $7.05 | · | · | · | $4.27 | · | · | · | $4.35 | · | · | |
| Cash / Share | $25.00 | $29.41 | · | $21.83 | $19.62 | $30.22 | · | $36.70 | $21.96 | $22.90 | · | $21.22 | · | · | · | · | |
| EPS (TTM) | $14.63 | $0.11 | · | $-6.21 | $-6.87 | $7.36 | · | $7.08 | $5.80 | $4.83 | · | $0.85 | $-1.60 | $-2.57 | · | $-0.37 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.60B | $4.44B | · | $4.16B | $4.09B | $4.06B | · | $3.99B | $3.91B | $3.84B | · | $3.79B | $3.76B | $3.74B | · | $3.58B | |
| Net Income TTM | $941M | $29M | · | $-368M | $-405M | $482M | · | $463M | $395M | $331M | · | $80M | $-87M | $-156M | · | $-19M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | 16.5 | 1718.6 | · | -21.2 | -15.4 | 16.9 | · | 15.7 | 18.4 | 24.9 | · | 152.3 | -77.5 | -56.9 | · | -360.2 | |
| P/S | 3.4 | 2.7 | · | 1.9 | 1.6 | 1.9 | · | 1.7 | 1.7 | 2.0 | · | 2.1 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| EV / Revenue | 4.0 | 3.5 | · | 2.9 | 2.6 | 2.7 | · | 2.7 | 2.8 | 3.1 | · | 3.3 | · | · | · | · | |
| Earnings Yield | 6.1% | 0.06% | · | -4.7% | -6.5% | 5.9% | · | 6.3% | 5.4% | 4.0% | · | 0.66% | -1.3% | -1.8% | · | -0.28% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Zysk netto | $-356M | $560M | $415M | $-224M | $-330M |
| Rozwodniony EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Brak danych dla tego sprawozdania
Zbyt mało danych fundamentalnych, aby utworzyć to sprawozdanie.
Brak danych dla tego sprawozdania
Zbyt mało danych fundamentalnych, aby utworzyć to sprawozdanie.
Właściciele instytucjonalni (13F) 687 emitentów · $15.8B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
687
Wartość posiadanych akcji
$15.8B
Nowe pozycje
138
Zamknięte pozycje
56
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 138 (+32 vs poprzedni kw.) | 56 (-21 vs poprzedni kw.) | 240 (+24 vs poprzedni kw.) | 188 (+19 vs poprzedni kw.) | +942K |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $1 438 254 453 | 5 968 603 | 9,11% | Akcje |
| FMR LLC | $1 110 709 035 | 4 609 326 | 7,04% | Akcje |
| VANGUARD GROUP INC | $1 005 914 140 | 5 917 142 | 6,37% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731 636 247 | 3 036 213 | 4,64% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $657 763 761 | 2 729 650 | 4,17% | Akcje |
| Capital World Investors | $650 043 082 | 2 697 610 | 4,12% | Akcje |
| FRANKLIN RESOURCES INC | $491 639 148 | 2 040 250 | 3,12% | Akcje |
| STATE STREET CORP | $481 895 662 | 1 999 816 | 3,05% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $412 909 300 | 1 713 592 | 2,62% | Akcje |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394 839 917 | 1 638 544 | 2,50% | Akcje |
| Bank of New York Mellon Corp | $380 253 849 | 1 578 013 | 2,41% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $359 935 093 | 1 522 568 | 2,28% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $357 440 125 | 1 483 031 | 2,26% | Akcje |
| AMERIPRISE FINANCIAL INC | $292 895 571 | 1 215 523 | 1,86% | Akcje |
| JPMORGAN CHASE & CO | $276 634 191 | 1 160 786 | 1,75% | Akcje |
| BANK OF AMERICA CORP /DE/ | $273 763 940 | 1 136 091 | 1,73% | Akcje |
| CITADEL ADVISORS LLC | $242 578 716 | 1 006 676 | 1,54% | Akcje |
| Swedbank AB | $233 281 128 | 968 092 | 1,48% | Akcje |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $192 606 598 | 799 297 | 1,22% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $184 072 164 | 763 880 | 1,17% | Akcje |
| UBS Group AG | $182 381 760 | 756 865 | 1,16% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $165 478 678 | 686 719 | 1,05% | Akcje |
| NORGES BANK | $158 279 458 | 656 843 | 1,00% | Akcje |
| MORGAN STANLEY | $151 734 512 | 629 680 | 0,96% | Akcje |
| Mariner, LLC | $146 630 968 | 608 615 | 0,93% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $135 442 731 | 562 073 | 0,86% | Akcje |
| Allianz Asset Management GmbH | $131 345 759 | 545 071 | 0,83% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129 891 746 | 539 037 | 0,82% | Akcje |
| NORTHERN TRUST CORP | $123 222 660 | 511 361 | 0,78% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $111 450 794 | 462 509 | 0,71% | Akcje |
| GMT Capital Corp | $109 279 895 | 453 500 | 0,69% | Akcje |
| Boston Trust Walden Corp | $106 779 349 | 443 123 | 0,68% | Akcje |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105 278 106 | 436 893 | 0,67% | Akcje |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103 893 734 | 431 148 | 0,66% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $96 439 086 | 400 212 | 0,61% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $95 008 929 | 394 277 | 0,60% | Akcje |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $91 259 201 | 378 715 | 0,58% | Akcje |
| Nuveen, LLC | $88 051 524 | 365 405 | 0,56% | Akcje |
| Sofinnova Investments, Inc. | $88 036 221 | 365 341 | 0,56% | Akcje |
| Polaris Capital Management, LLC | $79 270 937 | 328 966 | 0,50% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $77 695 234 | 322 427 | 0,49% | Akcje |
| GOLDENTREE ASSET MANAGEMENT LP | $70 838 675 | 294 435 | 0,45% | Akcje |
| Qube Research & Technologies Ltd | $70 056 003 | 290 725 | 0,44% | Akcje |
| GOLDMAN SACHS GROUP INC | $67 434 009 | 279 844 | 0,43% | Akcje |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66 815 854 | 277 279 | 0,42% | Akcje |
| Quantinno Capital Management LP | $65 906 960 | 273 506 | 0,42% | Akcje |
| BANK OF MONTREAL /CAN/ | $58 329 921 | 242 063 | 0,37% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $55 096 752 | 228 645 | 0,35% | Akcje |
| Tri Locum Partners LP | $53 427 868 | 221 720 | 0,34% | Akcje |
| Invesco Ltd. | $50 427 310 | 209 268 | 0,32% | Akcje |
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 zgłoszenia | 20 czerwca 2014 | · | Pierwotne zgłoszenie | · | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 zgłoszenia | 12 marca 2013 | · | Pierwotne zgłoszenie | · | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 zgłoszenia | 14 marca 2012 | · | Pierwotne zgłoszenie | Struktura kapitałowa | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 zgłoszenia | 30 września 2011 | · | Pierwotne zgłoszenie | · | SEC |
| Azur Pharma Limited | 28 września 2011 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 28 kwietnia 2005 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 56 insiderów · 18 dyrektorzy generalni · 20 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 8 września 2026 S | 143 394 | 0 | 1 | $-486 060 |
| Philip L Johnson | EVP & Chief Financial Officer | 30 czerwca 2026 F | 56 431 | 0 | 0 | $0 |
| Matthew P. Young | EVP & CFO | 6 marca 2019 S | 36 200 | 0 | 0 | $0 |
| Daniel N Swisher JR | President and COO | 5 marca 2023 F | 55 014 | 0 | 0 | $0 |
| Christopher J. Tovey | EVP, COO & Managing Director E | 5 lipca 2022 M | 14 663 | 0 | 0 | $0 |
| Russell J. Cox | EVP & COO | 11 grudnia 2017 M | 102 821 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 10 września 2026 S | 47 671 | 0 | 14 | $-11 500 359 |
| Mary Elizabeth Henderson | SVP, Technical Operations | 8 września 2026 F | 23 815 | 0 | 2 | $-1 418 523 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 27 sierpnia 2026 M | 65 686 | 0 | 7 | $-20 411 738 |
| Samantha Pearce | EVP, Chief Commercial Officer | 5 sierpnia 2026 F | 47 131 | 0 | 1 | $-1 625 977 |
| Patricia Carr | SVP, Chief Accounting Officer | 9 marca 2026 S | 6 512 | 0 | 7 | $-2 458 091 |
| Kim Sablich | EVP, GM of U.S. | 5 czerwca 2023 D | 28 478 | 0 | 0 | $0 |
| Finbar Larkin | SVP, Technical Operations | 6 marca 2023 M | 21 779 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | EVP, US Commercial | 12 marca 2020 S | 22 118 | 0 | 0 | $0 |
| Paul Treacy | SVP, Technical Operations | 12 sierpnia 2019 S | 16 418 | 0 | 0 | $0 |
| Iain Mcgill | SVP, Europe & Rest of World | 5 marca 2019 F | 24 938 | 0 | 0 | $0 |
| Karen J Wilson | SVP, Finance & PAO | 5 marca 2019 F | 18 385 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | EVP & General Counsel | 27 lutego 2019 M | 39 738 | 0 | 0 | $0 |
| Bruce C Cozadd | Dyrektor | 1 września 2026 S | 351 875 | 0 | 19 | $-26 393 546 |
| Patrick Kennedy | Dyrektor | 31 sierpnia 2026 F | 6 452 | 0 | 0 | $0 |
| Mark Douglas Smith | Dyrektor | 31 sierpnia 2026 F | 9 579 | 0 | 1 | $-266 746 |
| Jennifer E. Cook | Dyrektor | 31 sierpnia 2026 F | 10 736 | 0 | 0 | $0 |
| Laura Hamill | Dyrektor | 31 sierpnia 2026 F | 6 832 | 0 | 0 | $0 |
| Heather Ann Mcsharry | Dyrektor | 31 sierpnia 2026 F | 18 199 | 0 | 2 | $-1 089 119 |
| Rick E Winningham | Dyrektor | 31 sierpnia 2026 F | 9 466 | 0 | 2 | $-1 656 873 |
| Patrick G. Enright | Dyrektor | 31 sierpnia 2026 F | 21 278 | 0 | 0 | $0 |
| Ted W Love | Dyrektor | 31 sierpnia 2026 F | 2 389 | 0 | 0 | $0 |
| Norbert G Riedel | Dyrektor | 31 sierpnia 2026 F | 6 923 | 0 | 1 | $-655 680 |
| Seamus Mulligan | Dyrektor | 5 sierpnia 2026 A | 1 184 633 | 0 | 0 | $0 |
| Anne Oriordan | Dyrektor | 8 sierpnia 2025 F | 16 500 | 0 | 0 | $0 |
| Peter Gray | Dyrektor | 14 sierpnia 2023 S | 16 068 | 0 | 0 | $0 |
| Catherine A. Sohn | Dyrektor | 14 sierpnia 2023 S | 14 868 | 0 | 0 | $0 |
| Elmar Schnee | Dyrektor | 5 sierpnia 2021 S | 8 270 | 0 | 0 | $0 |
| Paul L Berns | Dyrektor | 5 sierpnia 2021 S | 8 290 | 0 | 0 | $0 |
| Bryan C Cressey | Dyrektor | 9 marca 2012 S | 27 631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Dyrektor | 10 marca 2011 A | · | 0 | 0 | $0 |
| Alexander E Albert | Dyrektor | 15 sierpnia 2008 A | · | 0 | 0 | $0 |
| Patel Jaimin | Dyrektor | 15 sierpnia 2007 A | · | 0 | 0 | $0 |
| Kenneth W O'Keefe | · | 2 grudnia 2025 F | 25 811 | 0 | 0 | $0 |
| Karen L. Smith | · | 5 marca 2018 F | 28 474 | 0 | 0 | $0 |
| Jeffrey K Tobias | · | 5 marca 2015 F | 38 484 | 0 | 0 | $0 |
| Fintan Keegan | · | 8 lipca 2014 M | 31 750 | 0 | 0 | $0 |
| Kathryn E Falberg | · | 5 marca 2014 F | 133 387 | 0 | 0 | $0 |
| James C Momtazee | · | 13 sierpnia 2013 S | 17 315 | 0 | 0 | $0 |
| Carol A Gamble | · | 9 marca 2012 S | 32 213 | 0 | 0 | $0 |
| Alan Sebulsky | · | 9 marca 2012 S | 54 355 | 0 | 0 | $0 |
| Samuel D Colella | · | 11 stycznia 2012 M | 38 347 | 0 | 0 | $0 |
| Michael W Michelson | · | 11 stycznia 2012 M | 13 885 | 0 | 0 | $0 |
| Mark G. Eller | · | 13 sierpnia 2011 M | 4 151 | 0 | 0 | $0 |
| Michael A. Desjardin | · | 13 sierpnia 2011 M | 14 574 | 0 | 0 | $0 |
| Janne Lt Wissel | · | 31 maja 2011 J | 48 544 | 0 | 0 | $0 |
| Joan Colligan | · | 30 listopada 2010 J | 14 424 | 0 | 0 | $0 |
| Robert M Myers | · | 30 listopada 2010 J | 156 898 | 0 | 0 | $0 |
| James B Tananbaum | · | 25 sierpnia 2010 A | 21 366 | 0 | 0 | $0 |
| Samuel R Saks | · | 21 stycznia 2009 A | 358 868 | 0 | 0 | $0 |
| Matthew K Fust | · | 28 listopada 2008 J | 58 948 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 61 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IHE · iShares Trust | 3,45% | 232 236 SH | 11 września 2026 | Dziennie |
| PJP · Invesco Exchange-Traded Fund Trust | 2,92% | 68 707 SH | 2 października 2026 | Dziennie |
| XMMO · Invesco Exchange-Traded Fund Trust | 2,29% | 699 736 SH | 2 października 2026 | Dziennie |
| PILL · Direxion Shares ETF Trust | 1,25% | 1 023 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,01% | 4 592 SH | 2 października 2026 | Dziennie |
| RFG · Invesco Exchange-Traded Fund Trust | 0,96% | 13 808 SH | 2 października 2026 | Dziennie |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,79% | 61 910 SH | 19 sierpnia 2026 | Dziennie |
| PDP · Invesco Exchange-Traded Fund Trust | 0,64% | 40 761 SH | 2 października 2026 | Dziennie |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 14 802 NS | 31 lipca 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,54% | 27 352 NS | 31 lipca 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,49% | 8 679 SH | 2 października 2026 | Dziennie |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,41% | 101 353 SH | 19 sierpnia 2026 | Dziennie |
| MIDU · Direxion Shares ETF Trust | 0,34% | 921 NS | 31 lipca 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,32% | 11 363 SH | 19 sierpnia 2026 | Dziennie |
| VBR · VANGUARD INDEX FUNDS | 0,31% | 867 777 SH | 19 sierpnia 2026 | Dziennie |
| VFMF · VANGUARD WELLINGTON FUND | 0,28% | 8 083 SH | 19 sierpnia 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,28% | 168 574 NS | 31 lipca 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,24% | 19 561 SH | 19 sierpnia 2026 | Dziennie |
| IYH · iShares Trust | 0,23% | 34 871 SH | 11 września 2026 | Dziennie |
| ESML · iShares Trust | 0,22% | 25 740 SH | 11 września 2026 | Dziennie |
| DFAT · Dimensional ETF Trust | 0,22% | 123 193 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,20% | 166 548 SH | 19 sierpnia 2026 | Dziennie |
| SMMD · iShares Trust | 0,20% | 31 945 SH | 11 września 2026 | Dziennie |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,18% | 9 978 SH | 2 października 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,17% | 719 903 SH | 19 sierpnia 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | 0,17% | 1 366 973 SH | 19 sierpnia 2026 | Dziennie |
| IWS · iShares Trust | 0,14% | 88 598 SH | 11 września 2026 | Dziennie |
| WSML · iShares Trust | 0,13% | 3 647 SH | 11 września 2026 | Dziennie |
| IWR · iShares Trust | 0,11% | 244 305 SH | 11 września 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 3 144 SH | 2 października 2026 | Dziennie |
| XT · iShares Trust | 0,09% | 13 710 SH | 11 września 2026 | Dziennie |
| DFAC · Dimensional ETF Trust | 0,08% | 147 012 NS | 31 lipca 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,08% | 45 748 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,05% | 7 084 NS | 31 lipca 2026 | N-PORT |
| IUSG · iShares Trust | 0,04% | 55 258 SH | 11 września 2026 | Dziennie |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,04% | 36 014 SH | 19 sierpnia 2026 | Dziennie |
| IWD · iShares Trust | 0,04% | 133 301 SH | 11 września 2026 | Dziennie |
| DSI · iShares Trust | 0,04% | 8 411 SH | 11 września 2026 | Dziennie |
| PRF · Invesco Exchange-Traded Fund Trust | 0,04% | 15 040 SH | 2 października 2026 | Dziennie |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1 371 SH | 2 października 2026 | Dziennie |
| DFAU · Dimensional ETF Trust | 0,03% | 13 729 NS | 31 lipca 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0,02% | 39 438 SH | 11 września 2026 | Dziennie |
| DXUV · Dimensional ETF Trust | 0,02% | 467 NS | 31 lipca 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2 648 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,02% | 17 349 NS | 31 lipca 2026 | N-PORT |
| ITOT · iShares Trust | 0,02% | 81 293 SH | 11 września 2026 | Dziennie |
| IWB · iShares Trust | 0,02% | 41 012 SH | 11 września 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1 892 855 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 9 995 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 5 021 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,02% | 13 490 SH | 19 sierpnia 2026 | Dziennie |
| IWV · iShares Trust | 0,02% | 16 075 SH | 10 września 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 49 429 SH | 19 sierpnia 2026 | Dziennie |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1 238 SH | 2 października 2026 | Dziennie |
| NEAR · iShares U.S. ETF Trust | 0,00% | 200 000 SH | 9 września 2026 | Dziennie |
| IJH · iShares Trust | · | 2 201 423 SH | 11 września 2026 | Dziennie |
| IJK · iShares Trust | · | 363 871 SH | 11 września 2026 | Dziennie |
| XJH · iShares Trust | · | 8 572 SH | 8 września 2026 | Dziennie |
| ISCB · iShares Trust | · | 2 820 SH | 11 września 2026 | Dziennie |
| ISCV · iShares Trust | · | 13 894 SH | 11 września 2026 | Dziennie |
| SMMV · iShares Trust | · | 4 635 SH | 19 sierpnia 2026 | Dziennie |
JAZZ Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 26 analityków
KUP
Średni cel
$300.00
+27,3%
7 26,9%
Mocne kupno
17 65,4%
Kup
2 7,7%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
22 analityków · 2026-10-03Średnia cel $294.27 +24,9%
Teraz
Aktualna cena $235.67
Niski$225.00
Średnia$294.27
Wysoki$337.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 3, 2026